Skip to main content
Top
Published in: Pediatric Nephrology 3/2010

01-03-2010 | Brief Report

A case of minimal change disease in a Fabry patient

Authors: Yuri A. Zarate, Larry Patterson, Hong Yin, Robert J. Hopkin

Published in: Pediatric Nephrology | Issue 3/2010

Login to get access

Abstract

Fabry disease is an X-linked lysosomal storage disorder caused by mutations of the GLA gene and deficiency in α-galactosidase A activity. Glycosphingolipids accumulation causes renal injury that manifests early during childhood as tubular dysfunction and later in adulthood as proteinuria and renal insufficiency. Nephrotic syndrome as the first evidence of Fabry-related kidney damage is rare. We report the case of a teenager with known Fabry disease and normal renal function who developed acute nephrotic syndrome. He was found to have typical glycosphingolipids accumulation with no other findings suggestive of alternative causes of nephrotic syndrome on kidney biopsy. After treatment with enzyme replacement therapy and oral steroids, he went into complete remission from nephrotic syndrome, a response that is atypical for Fabry disease patients who develop heavy proteinuria as a result of longstanding disease and chronic renal injury. The nephrotic syndrome in this patient appears to have developed secondary to minimal change disease. We recommend considering immunotherapy in addition to enzyme replacement therapy in those patients with confirmed Fabry disease and acute nephrotic syndrome with clinical and microscopic findings suggestive of minimal change disease.
Literature
2.
go back to reference Branton M, Schiffmann R, Kopp JB (2002) Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol 13(Suppl 2):S139–S143PubMed Branton M, Schiffmann R, Kopp JB (2002) Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol 13(Suppl 2):S139–S143PubMed
3.
go back to reference Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G, Widmer U, Beck M, FOS European Investigators (2006) Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 95:86–92CrossRefPubMed Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G, Widmer U, Beck M, FOS European Investigators (2006) Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 95:86–92CrossRefPubMed
4.
go back to reference Ries M, Clarke JT, Whybra C, Timmons M, Robinson C, Schlaggar BL, Pastores G, Lien YH, Kampmann C, Brady RO, Beck M, Schiffmann R (2006) Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 118:924–932 Ries M, Clarke JT, Whybra C, Timmons M, Robinson C, Schlaggar BL, Pastores G, Lien YH, Kampmann C, Brady RO, Beck M, Schiffmann R (2006) Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 118:924–932
5.
go back to reference Ries M, Gupta S, Moore DF, Sachdev V, Quirk JM, Murray GJ, Rosing DR, Robinson C, Schaefer E, Gal A, Dambrosia JM, Garman SC, Brady RO, Schiffmann R (2005) Pediatric Fabry disease. Pediatrics 115:e344–e355 Ries M, Gupta S, Moore DF, Sachdev V, Quirk JM, Murray GJ, Rosing DR, Robinson C, Schaefer E, Gal A, Dambrosia JM, Garman SC, Brady RO, Schiffmann R (2005) Pediatric Fabry disease. Pediatrics 115:e344–e355
6.
go back to reference Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, Lemay R, Tylki-Szymanska A, Wilcox WR (2008) Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 64:550–555 Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, Lemay R, Tylki-Szymanska A, Wilcox WR (2008) Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 64:550–555
7.
go back to reference Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin Iii HA, Kopp JB (2002) Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81:122–138 Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin Iii HA, Kopp JB (2002) Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81:122–138
8.
go back to reference Cybulla M, Schaefer E, Wendt S, Ling H, Krober SM, Hovelborn U, Schandelmaier S, Rohrbach R, Neumann HP (2005) Chronic renal failure and proteinuria in adulthood: Fabry disease predominantly affecting the kidneys. Am J Kidney Dis 45:e82–e89 Cybulla M, Schaefer E, Wendt S, Ling H, Krober SM, Hovelborn U, Schandelmaier S, Rohrbach R, Neumann HP (2005) Chronic renal failure and proteinuria in adulthood: Fabry disease predominantly affecting the kidneys. Am J Kidney Dis 45:e82–e89
9.
go back to reference Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C (2008) Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 23:1600–1607CrossRefPubMed Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C (2008) Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 23:1600–1607CrossRefPubMed
10.
go back to reference Yoshida A, Morozumi K, Takeda A, Koyama K, Oikawa T (1994) Fabry-like laminated myelin body associated with IgA nephropathy. Nippon Jinzo Gakkai Shi 36:1303–1307PubMed Yoshida A, Morozumi K, Takeda A, Koyama K, Oikawa T (1994) Fabry-like laminated myelin body associated with IgA nephropathy. Nippon Jinzo Gakkai Shi 36:1303–1307PubMed
11.
go back to reference Kawamura O, Sakuraba H, Itoh K, Suzuki Y, Doi M, Kuwabara H, Oshima S, Abe S, Warabi H, Yoshizawa N (1997) Subclinical Fabry’s disease occurring in the context of IgA nephropathy. Clin Nephrol 47:71–75 Kawamura O, Sakuraba H, Itoh K, Suzuki Y, Doi M, Kuwabara H, Oshima S, Abe S, Warabi H, Yoshizawa N (1997) Subclinical Fabry’s disease occurring in the context of IgA nephropathy. Clin Nephrol 47:71–75
12.
go back to reference Pisani A, Sessa A, Sabbatini M, Andreucci MV, Fusco C, Balletta M, Cianciaruso B (2005) Fabry nephropathy in a female with superposed IgA glomerulonephritis. G Ital Nefrol 22:385–389 Pisani A, Sessa A, Sabbatini M, Andreucci MV, Fusco C, Balletta M, Cianciaruso B (2005) Fabry nephropathy in a female with superposed IgA glomerulonephritis. G Ital Nefrol 22:385–389
13.
go back to reference Shimazu K, Tomiyoshi Y, Aoki S, Sakemi T, Sugihara H (2002) Crescentic glomerulonephritis in a patient with heterozygous Fabry’s disease. Nephron 92:456–458CrossRefPubMed Shimazu K, Tomiyoshi Y, Aoki S, Sakemi T, Sugihara H (2002) Crescentic glomerulonephritis in a patient with heterozygous Fabry’s disease. Nephron 92:456–458CrossRefPubMed
14.
go back to reference Singh HK, Nickeleit V, Kriegsmann J, Harris AA, Jennette JC, Mihatsch MJ (2001) Coexistence of Fabry’s disease and necrotizing and crescentic glomerulonephritis. Clin Nephrol 55:73–79PubMed Singh HK, Nickeleit V, Kriegsmann J, Harris AA, Jennette JC, Mihatsch MJ (2001) Coexistence of Fabry’s disease and necrotizing and crescentic glomerulonephritis. Clin Nephrol 55:73–79PubMed
15.
go back to reference Alroy J, Sabnis S, Kopp JB (2002) Renal pathology in Fabry disease. J Am Soc Nephrol 13(Suppl 2):S134–S138PubMed Alroy J, Sabnis S, Kopp JB (2002) Renal pathology in Fabry disease. J Am Soc Nephrol 13(Suppl 2):S134–S138PubMed
16.
go back to reference Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O'Callaghan M (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62:1933–1946 Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O'Callaghan M (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62:1933–1946
17.
go back to reference Tahir H, Jackson LL, Warnock DG (2007) Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 18:2609–2617CrossRefPubMed Tahir H, Jackson LL, Warnock DG (2007) Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 18:2609–2617CrossRefPubMed
18.
go back to reference Fischer EG, Moore MJ, Lager DJ (2006) Fabry disease: a morphologic study of 11 cases. Mod Pathol 19:1295–1301CrossRefPubMed Fischer EG, Moore MJ, Lager DJ (2006) Fabry disease: a morphologic study of 11 cases. Mod Pathol 19:1295–1301CrossRefPubMed
19.
go back to reference Saha TC, Singh H (2006) Minimal change disease: a review. South Med J 99:1264–1270PubMed Saha TC, Singh H (2006) Minimal change disease: a review. South Med J 99:1264–1270PubMed
20.
go back to reference Anochie I, Eke F, Okpere A (2006) Childhood nephrotic syndrome: change in pattern and response to steroids. J Natl Med Assoc 98:1977–1981PubMed Anochie I, Eke F, Okpere A (2006) Childhood nephrotic syndrome: change in pattern and response to steroids. J Natl Med Assoc 98:1977–1981PubMed
Metadata
Title
A case of minimal change disease in a Fabry patient
Authors
Yuri A. Zarate
Larry Patterson
Hong Yin
Robert J. Hopkin
Publication date
01-03-2010
Publisher
Springer-Verlag
Published in
Pediatric Nephrology / Issue 3/2010
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-009-1353-0

Other articles of this Issue 3/2010

Pediatric Nephrology 3/2010 Go to the issue